Sign In

Precision Hepatology in Clinical Practice

Date/Time

  • Saturday, November 9, 8:00 am – 5:00 pm

Program Chairs

  • Jorge A. Bezerra, MD, FAASLD
  • Andrew P. Keaveny, MD, FRCPI, FAASLD
  • Rebecca G. Wells, MD

Session Description / Needs Statement

Hepatology practice is undergoing major changes fueled by the discovery of disease biomarkers and digital strategies to stage and monitor clinical courses. Once glimpses of a possible future, minimally invasive tests and electronic resources are increasingly available in the clinic. In this Postgraduate Course, experts review how these advances improve care protocols and allow for precise, even customized clinical approaches.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Review evidence-based evaluation and management options available for a spectrum of liver diseases, their benefits and risks, and strategies to tailor treatment plans to individual patients
  • Discuss the value of circulating and tissue biomarkers in making rational decisions for optimal patient care
  • Apply information on minimally invasive tests and digital tools to identify biomarkers to the clinical practice of hepatology

Continuing Education

  • CME – 7.0 AMA PRA Category 1 Credits™
  • CE – 6.5 Contact Hours
  • ABIM MOC – 7.0 Points
  • ABP MOC – 7.0 Points
  • Eligible for 3.5 pharmacology hours

To view full programming being offered at The Liver Meeting®, visit the 2019 Online Program. [Coming Summer 2019]

Session I: Precision Medicine in 2019

Moderators: TBD

  • 8:00 am – 8:05 am
    Welcome and Introductions
  • 8:05 am – 8:25 am
    The Spectrum of Precision Medicine
    TBD
  • 8:25 am – 8:45 am
    Influence of the Microbiome on Liver Disease Phenotype and Outcome
    TBD
  • 8:45 am – 9:05 am
    Precision Medicine and Patients at Risk for Drug-induced Liver Injury*
    TBD
  • 9:05 am - 9:25 am
    Clinical Models and Risk Assessment: Acute-on-Chronic Liver Failure as a Paradigm
    TBD

Session II: Evolution of Disease and Reversing Fibrosis

Moderators: TBD

  • 9:25 am – 9:45 am
    Non-alcoholic Fatty Liver Disease: Non-invasive Phenotyping
    TBD
  • 9:45 am – 10:05 am
    Phenotyping NAFLD: Risk Stratification and Managing Co-Morbidities*
    TBD
  • 10:05 am – 10:25 am
    Reversing Liver Fibrosis: Predicting and Monitoring Structural Changes*
    TBD
  • 10:25 am – 10:40 am
    Break

Session III: Autoimmune Diseases and Cholestasis

Moderators: TBD

  • 10:40 am – 11:00 am
    Precision Therapy in Patients with Primary Biliary Cholangitis*
    TBD
  • 11:00 am – 11:20 am
    Predictors of Disease Progression and Complications of Primary Sclerosing Cholangitis
    TBD
  • 11:20 am – 11:40 am
    Autoimmune Liver Disease in Younger Patient: Crossing Phenotypic Boundaries*
    TBD
  • 11:40 am – 12:00 pm
    Biliary Atresia: Biomarkers of Disease and Predictors of Outcome*
    TBD
  • 12:00 pm – 1:30 pm
    Intermission / Meet-the-Professor Luncheons

Session IV: Hepatic Neoplasms

Moderators: TBD

  • 1:30 pm – 1:50 pm
    Managing HCV Cirrhotic Patients After Achieving SVR: Who Will Progress to Developing Hepatocellular Carcinoma?*
    TBD
  • 1:50 pm – 2:10 pm
    Non-invasive Assessment of Small Liver Lesions
    TBD
  • 2:10 pm – 2:30 pm
    Precision Medicine to Guide Therapy in Liver Cancer
    TBD
  • 2:30 pm – 2:50 pm
    Emerging Treatment Options for HCC and Cholangiocarcinoma*
    TBD
  • 2:50 pm – 3:15 pm
    Break

Session V: Questions, Controversies and Value of Care

Moderators: TBD

  • 3:15 pm – 3:35 pm
    Genetic Testing in Adults with Liver Disease: Improving Diagnostic Algorithms
    TBD
  • 3:35 pm – 3:55 pm
    Precision Treatment of HBV: Envisioning Curative Therapies*
    TBD
  • 3:55 pm – 4:15 pm
    Personalizing Longitudinal Care of Patients with Cirrhosis
    TBD
  • 4:15 pm – 4:35 pm
    Case-based Debate: Balancing the Costs and Benefits of Individualized Medicine*
    TBD
  • 4:35 pm – 4:55 pm
    From Discovery Science to Clinical Care: Where Do We Want to Go?
    TBD
  • 4:55 pm – 5:00 pm
    Closing Remarks